Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,072 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.
Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, Griffin TA, Alexeeva E, Bohnsack JF, Zeft A, Horneff G, Vehe RK, Staņēviča V, Tarvin S, Trachana M, Del Río AQ, Huber AM, Kietz D, Orbán I, Dare J, Foeldvari I, Quartier P, Dominique A, Simon TA, Martini A, Brunner HI, Ruperto N; for PRINTO and the Pediatric Rheumatology Collaborative Study Group (PRCSG)§. Lovell DJ, et al. Among authors: martini a. Rheumatology (Oxford). 2024 Sep 1;63(SI2):SI195-SI206. doi: 10.1093/rheumatology/keae025. Rheumatology (Oxford). 2024. PMID: 38243722 Free PMC article.
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis.
Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. Wallace CA, et al. Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36. doi: 10.1002/acr.20497. Arthritis Care Res (Hoboken). 2011. PMID: 21717596 Free article.
HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.
Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, Ilowite NT, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg A, Wedderburn LR, Anton J, Schwarz T, Hinks A, Bilginer Y, Park J, Cobb J, Satorius CL, Han B, Baskin E, Signa S, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group; Childhood Arthritis Prospective Study (CAPS) Group; Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators; Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group; Biologically Based Outcome Predictors in JIA (BBOP) Group; de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P; International Childhood Arthritis Genetics (INCHARGE) Consortium. Ombrello MJ, et al. Among authors: martini a. Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15970-5. doi: 10.1073/pnas.1520779112. Epub 2015 Nov 23. Proc Natl Acad Sci U S A. 2015. PMID: 26598658 Free PMC article.
IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.
Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM; INCHARGE Consortium; Thomson W, Kastner DL, Woo P, Ombrello MJ. Arthur VL, et al. Among authors: martini a. Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28. Arthritis Rheumatol. 2018. PMID: 29609200 Free PMC article.
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.
Brunner HI, Akikusa JD, Al-Abadi E, Bohnsack JF, Boteanu AL, Chedeville G, Cuttica R, De La Pena W, Jung L, Kasapcopur O, Kobusinska K, Schulert GS, Neiva C, Rivas-Chacon R, Rizo Rodriguez JC, Vazquez-Del Mercado M, Wagner-Weiner L, Weiss JE, Wouters C, Posner H, Wouters A, Chang C, White C, Kanik K, Liu S, Martini A, Lovell DJ, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Brunner HI, et al. Among authors: martini a. Ann Rheum Dis. 2024 Oct 21;83(11):1561-1571. doi: 10.1136/ard-2023-225094. Ann Rheum Dis. 2024. PMID: 38849152 Free PMC article.
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
Brunner HI, Schulert GS, Sproles A, Thornton S, Cornejo GV, Antón J, Cuttica R, Henrickson M, Foeldvari I, Kingsbury DJ, Askelson M, Liu J, Mukherjee S, Wong RL, Lovell DJ, Martini A, Ruperto N, Grom AA; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Brunner HI, et al. Among authors: martini a. Arthritis Res Ther. 2024 Jun 25;26(1):125. doi: 10.1186/s13075-024-03347-0. Arthritis Res Ther. 2024. PMID: 38918871 Free PMC article. Clinical Trial.
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.
Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Alexeeva E, Appenzeller S, Chasnyk V, Griffin T, Suarez CN, Knupp-Oliveira S, Zeft A, Aviel YB, De Ranieri D, Gottlieb BS, Levy DM, Rabinovich CE, Silva CA, Spivakovsky Y, Uziel Y, Ringold S, Xu XL, Leu JH, Lam E, Wang Y, Lovell DJ, Martini A, Ruperto N; Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO). Brunner HI, et al. Among authors: martini a. J Rheumatol. 2024 Nov 1;51(11):1125-1134. doi: 10.3899/jrheum.2024-0298. J Rheumatol. 2024. PMID: 39089836 Free article. Clinical Trial.
Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
Brunner HI, Schulert GS, Sproles A, Thornton S, Cornejo GV, Antón J, Cuttica R, Henrickson M, Foeldvari I, Kingsbury DJ, Askelson M, Liu J, Mukherjee S, Wong RL, Lovell DJ, Martini A, Ruperto N, Grom AA; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Brunner HI, et al. Among authors: martini a. Arthritis Res Ther. 2024 Aug 31;26(1):154. doi: 10.1186/s13075-024-03385-8. Arthritis Res Ther. 2024. PMID: 39217348 Free PMC article. No abstract available.
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis.
Vojinović J, Foeldvari I, Dehoorne J, Panaviene V, Susic G, Horneff G, Stanevica V, Kobusinska K, Zuber Z, Dobrzyniecka B, Avcin T, Borlenghi C, Arthur E, Zang C, Tsekouras V, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Vojinović J, et al. Among authors: martini a. Rheumatol Ther. 2024 Dec;11(6):1437-1440. doi: 10.1007/s40744-024-00703-z. Epub 2024 Sep 12. Rheumatol Ther. 2024. PMID: 39264536 Free PMC article.
New classification criteria for juvenile idiopathic arthritis.
Chen K, Zeng H, Togizbayev G, Martini A, Zeng H. Chen K, et al. Among authors: martini a. Int J Rheum Dis. 2023 Oct;26(10):1889-1892. doi: 10.1111/1756-185X.14813. Int J Rheum Dis. 2023. PMID: 37807617 No abstract available.
2,072 results